Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL

This study is testing CAR-NK cell therapy — immune cells from donated cord blood that have been engineered to target and kill cancer cells with a CD19 protein on their surface — in people with relapsed or treatment-resistant B-cell non-Hodgkin's lymphoma. **You may be eligible if...** - You are 18–75 years old and have been diagnosed with relapsed or treatment-resistant B-cell non-Hodgkin's lymphoma (such as diffuse large B-cell lymphoma, mantle cell lymphoma, or similar types) - Your cancer has not responded to at least 2 lines of treatment, including a CD20 antibody (like rituximab) and anthracycline chemotherapy - Your cancer cells test positive for the CD19 protein - You are in reasonably good health (ECOG performance score 0–2) **You may NOT be eligible if...** - You have HIV, active hepatitis B or C, or uncontrolled infections - You have received prior anti-CD19 therapy - You have serious heart, liver, or kidney problems Talk to your doctor to see if this trial is right for you.